Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $9.50.

QNCX has been the topic of several analyst reports. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Maxim Group started coverage on Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target on the stock. Rodman & Renshaw began coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective for the company. Brookline Capital Management began coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd.

Quince Therapeutics Stock Performance

Shares of QNCX stock opened at $1.88 on Thursday. The firm has a 50 day moving average of $1.85 and a two-hundred day moving average of $1.13. The stock has a market capitalization of $82.72 million, a PE ratio of -1.52 and a beta of 0.64. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45.

Hedge Funds Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC grew its stake in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent reporting period. 30.75% of the stock is owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.